Asterion Cannabis Inc. (“Asterion” or the “Company”), is pleased to announce the voting results from the Company’s 2020 annual general meeting of shareholders (the “Meeting”) held on Friday, January 24, 2020, in Vancouver, British Columbia. A total of 45,613,167 common shares were voted at the Meeting, representing 68.36% of the outstanding common shares of the Company, as at the record date for the Meeting. All matters submitted to shareholders for approval, as set out in the Company’s notice of meeting and management information circular, dated January 13, 2020, were unanimously approved by the votes cast at the Meeting.
Shareholders re-appointed Smythe LLP, Chartered Professional Accountants as the auditor of the Company for the ensuing year at the remuneration to be fixed by the directors of the Company and approved the Company’s 10% rolling stock option plan.
The number of directors of the Company has remained at six and management’s nominees for election as director, Stephen Van Deventer, Kimberly Van Deventer, Shabira Rajan, Hamish Sutherland, Peter Haukedal, and Robert Coltura, were all elected as directors of the Company.
Stephen Van Deventer, Chairman and CEO, commented, “We are extremely pleased to have Mr. Coltura join the Board of Directors of Asterion. Collectively, the boards diverse experience and backgrounds will be a valuable asset as the Company advances into the next phase of its development.”
Mr. Coltura is a businessman and is the President and principal shareholder of Matalia Investments Ltd., a company that provides management consulting and corporate finance services to public and private companies. Mr. Coltura is also the President and Chief Executive Officer of Fiorentina Minerals Inc., the President of Coltura Financial Corp and Coltura Properties, which has commercial properties and hotels in North America. With over 20 years of experience in the public sector, as a director and officer, and in successful business development, he works with companies to strengthen their positions within their industry.
Asterion Cannabis Inc. is a Canadian medicinal cannabis company with a wholly-owned Australian subsidiary, Asterion (Australia) Pty Ltd. With its cultivation to market strategy, the company’s focus is leading and advancing cannabis agriculture, producing the highest quality, lowest cost, genetically uniform cannabis strains and cannabinoid products. The Australian government formally recognizes the company with a Major Project Status and the company has been granted a medicinal cannabis license, a cannabis research license, and a manufacture license from the Australian Office of Drug Control.
Led by a highly experienced team with over 200 years of combined successful track records spanning – North America, Europe, the Middle East, and Asia-Pacific. Management experience with large scale projects includes medicinal cannabis, renewable energy, and capital markets.
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chief Executive Officer
For further information, please contact:
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. Other than statements of historical fact, all statements included in this news release, including, without limitation, statements regarding the Company’s anticipated business plans and prospects of success in executing its plans, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Various risks and uncertainties could cause actual results to differ materially from Asterion’s expectations. Other factors such as general economic, market or business conditions, future prices of cannabis, changes in the financial markets and in the demand and market price for cannabis, or changes in laws, regulations and policies affecting the biotechnology or cannabis industry, and delays in obtaining governmental and regulatory approvals, may also adversely affect the future results or performance of the Company. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.